Table I.
Association between KL methylation profiles and clinicopathological features of patients with ovarian cancer.
| KL methylation profile | ||||
|---|---|---|---|---|
| Clinicopathological features | N (%) | 0 unmethylated, n (%) | 1 hypermethylated, n (%) | P-valuea |
| Age, years | ||||
| <50 | 40 (63.5) | 19 (79.2) | 21 (55.3) | 0.064 |
| >50 | 22 (34.9) | 5 (20.8) | 17 (44.7) | |
| NA | 1 (1.6) | |||
| Diagnosis method | ||||
| Surgery | 58 (92.1) | 22 (91.7) | 36 (94.7) | 0.637 |
| Biopsy | 4 (6.3) | 2 (8.3) | 2 (5.3) | |
| NA | 1 (1.6) | |||
| Tumor site | ||||
| Right | 11 (17.5) | 4 (16.7) | 7 (18.4) | 0.039b |
| Left | 11 (17.5) | 8 (33.3) | 3 (7.9) | |
| Bilateral | 40 (63.5) | 12 (50.0) | 28 (73.7) | |
| NA | 1 (1.6) | |||
| Tumor size, cm | ||||
| 1-5 | 18 (28.6) | 9 (39.1) | 9 (23.7) | 0.370 |
| 6-10 | 16 (25.4) | 6 (26.1) | 10 (26.3) | |
| >10 | 27 (42.9) | 8 (34.8) | 19 (50.0) | |
| NA | 2 (3.2) | |||
| Tumor subtype | ||||
| Serous | 30 (47.6) | 12 (50.0) | 18 (47.4) | <0.001b |
| Mucinous | 17 (27.0) | 1 (4.2) | 16 (42.1) | |
| Other | 14 (22.2) | 11 (45.8) | 3 (7.9) | |
| NA | 2 (3.2) | 0 (0.0) | 1 (2.6) | |
| Tumor grade | ||||
| Undetermined grade (GX) | 10 (15.9) | 5 (23.8) | 5 (16.1) | 0.825 |
| Low malignant potential (GB) | 5 (7.9) | 2 (9.5) | 3 (9.7) | |
| Well-differentiated (G1) | 3 (4.8) | 2 (9.5) | 1 (3.2) | |
| Moderately differentiated (G2) | 15 (23.8) | 5 (23.8) | 10 (32.3) | |
| Undifferentiated (G3 to G4) | 19 (30.2) | 7 (33.3) | 12 (38.7) | |
| NA | 11 (17.5) | |||
| Lymph node status | ||||
| Positive | 11 (17.5) | 2 (22.2) | 9 (56.3) | 0.208 |
| Negative | 14 (22.2) | 7 (77.8) | 7 (43.8) | |
| NA | 38 (60.3) | |||
| Body mass index | ||||
| <23 | 2 (3.2) | 0 (0.0) | 2 (9.5) | 0.118 |
| 23-26 | 12 (19.0) | 8 (47.1) | 4 (19.0) | |
| >26 | 24 (38.1) | 9 (52.9) | 15 (71.4) | |
| NA | 25 (39.7) | |||
| Parity | ||||
| Parous | 29 (46.0) | 10 (62.5) | 19 (73.1) | 0.510 |
| Nulliparous | 13 (20.6) | 6 (37.5) | 7 (26.9) | |
| NA | 21 (33.3) | |||
| Menopausal status | ||||
| Premenopausal | 41 (65.1) | 19 (79.2) | 22 (57.9) | 0.104 |
| Postmenopausal | 21 (33.3) | 5 (20.8) | 16 (42.1) | |
| NA | 1 (1.6) | |||
| Tumor stage | ||||
| Stage I | 16 (25.4) | 8 (38.1) | 8 (22.9) | 0.660 |
| Stage II | 4 (6.3) | 1 (4.8) | 3 (8.6) | |
| Stage III | 31 (49.2) | 10 (47.6) | 21 (60.0) | |
| Stage IV | 5 (7.9) | 2 (9.5) | 3 (8.6) | |
| NA | 7 (11.1) | |||
| Endpoint status | ||||
| Living | 24 (38.1) | 11 (73.3) | 13 (41.9) | 0.063 |
| Deceased | 22 (34.9) | 4 (26.7) | 18 (58.1) | |
| NA | 17 (27.0) | |||
| Recurrence status | ||||
| No | 20 (31.7) | 7 (41.2) | 13 (48.1) | 0.760 |
| Yes | 24 (83.1) | 10 (58.8) | 14 (51.9) | |
| NA | 19 (30.2) | |||
aP-values were calculated using Fisher-Freeman-Halton Exact test.
bP<0.05. KL, Klotho; NA, not available.